536 related articles for article (PubMed ID: 9034595)
1. Immunotherapy II: Antigens, receptors and costimulation.
Searle PF; Young LS
Cancer Metastasis Rev; 1996 Sep; 15(3):329-49. PubMed ID: 9034595
[TBL] [Abstract][Full Text] [Related]
2. Genetically modified tumour vaccines--where we are today.
Nawrocki S; Mackiewicz A
Cancer Treat Rev; 1999 Feb; 25(1):29-46. PubMed ID: 10212588
[TBL] [Abstract][Full Text] [Related]
3. Immune responses to tumour antigens: implications for antigen specific immunotherapy of cancer.
Jäger D; Jäger E; Knuth A
J Clin Pathol; 2001 Sep; 54(9):669-74. PubMed ID: 11533070
[TBL] [Abstract][Full Text] [Related]
4. CD28 co-stimulation via tumour-specific chimaeric receptors induces an incomplete activation response in Epstein-Barr virus-specific effector memory T cells.
Altvater B; Pscherer S; Landmeier S; Niggemeier V; Juergens H; Vormoor J; Rossig C
Clin Exp Immunol; 2006 Jun; 144(3):447-57. PubMed ID: 16734614
[TBL] [Abstract][Full Text] [Related]
5. Broadly expressed tumour-associated proteins as targets for cytotoxic T lymphocyte-based cancer immunotherapy.
Bendle GM; Holler A; Downs AM; Xue SA; Stauss HJ
Expert Opin Biol Ther; 2005 Sep; 5(9):1183-92. PubMed ID: 16120049
[TBL] [Abstract][Full Text] [Related]
6. Lessons from T cell responses to virus induced tumours for cancer eradication in general.
Melief CJ; Kast WM
Cancer Surv; 1992; 13():81-99. PubMed ID: 1423326
[TBL] [Abstract][Full Text] [Related]
7. Human effector T cells derived from central memory cells rather than CD8(+)T cells modified by tumor-specific TCR gene transfer possess superior traits for adoptive immunotherapy.
Wu F; Zhang W; Shao H; Bo H; Shen H; Li J; Liu Y; Wang T; Ma W; Huang S
Cancer Lett; 2013 Oct; 339(2):195-207. PubMed ID: 23791878
[TBL] [Abstract][Full Text] [Related]
8. Failure of cancer vaccines: the significant limitations of this approach to immunotherapy.
Bodey B; Bodey B; Siegel SE; Kaiser HE
Anticancer Res; 2000; 20(4):2665-76. PubMed ID: 10953341
[TBL] [Abstract][Full Text] [Related]
9. [Antitumor immunity and cellular cancer therapies].
Catros-Quemener V; Bouet F; Genetet N
Med Sci (Paris); 2003 Jan; 19(1):43-53. PubMed ID: 12836191
[TBL] [Abstract][Full Text] [Related]
10. Replicating viral vector platform exploits alarmin signals for potent CD8
Kallert SM; Darbre S; Bonilla WV; Kreutzfeldt M; Page N; Müller P; Kreuzaler M; Lu M; Favre S; Kreppel F; Löhning M; Luther SA; Zippelius A; Merkler D; Pinschewer DD
Nat Commun; 2017 May; 8():15327. PubMed ID: 28548102
[TBL] [Abstract][Full Text] [Related]
11. Effective therapeutic anticancer vaccines based on precision guiding of cytolytic T lymphocytes.
Melief CJ; Van Der Burg SH; Toes RE; Ossendorp F; Offringa R
Immunol Rev; 2002 Oct; 188():177-82. PubMed ID: 12445291
[TBL] [Abstract][Full Text] [Related]
12. Life or death of T cells with antigen-specific receptors--using T cells for cancer adoptive immunotherapy/gene therapy.
Ren-Heidenreich L; Lum LG
Curr Gene Ther; 2001 Sep; 1(3):253-5. PubMed ID: 12109140
[TBL] [Abstract][Full Text] [Related]
13. Tumour-specific CTL response requiring interactions of four different cell types and recognition of MHC class I and class II restricted tumour antigens.
Schirrmacher V; Schild HJ; Gückel B; von Hoegen P
Immunol Cell Biol; 1993 Aug; 71 ( Pt 4)():311-26. PubMed ID: 7901150
[TBL] [Abstract][Full Text] [Related]
14. Immunological Characterization of Whole Tumour Lysate-Loaded Dendritic Cells for Cancer Immunotherapy.
Rainone V; Martelli C; Ottobrini L; Biasin M; Texido G; Degrassi A; Borelli M; Lucignani G; Trabattoni D; Clerici M
PLoS One; 2016; 11(1):e0146622. PubMed ID: 26795765
[TBL] [Abstract][Full Text] [Related]
15. Autologous cellular vaccine overcomes cancer immunoediting in a mouse model of myeloma.
Mazzocco M; Martini M; Rosato A; Stefani E; Matucci A; Dalla Santa S; De Sanctis F; Ugel S; Sandri S; Ferrarini G; Cestari T; Ferrari S; Zanovello P; Bronte V; Sartoris S
Immunology; 2015 Sep; 146(1):33-49. PubMed ID: 25959091
[TBL] [Abstract][Full Text] [Related]
16. Immunization with tumor-associated epitopes fused to an endoplasmic reticulum translocation signal sequence affords protection against tumors with down-regulated expression of MHC and peptide transporters.
Sherritt M; Cooper L; Moss DJ; Kienzle N; Altman J; Khanna R
Int Immunol; 2001 Mar; 13(3):265-71. PubMed ID: 11222495
[TBL] [Abstract][Full Text] [Related]
17. Review: the application of dendritic cell-derived exosomes in tumour immunotherapy.
Quah B; O'Neill HC
Cancer Biother Radiopharm; 2000 Apr; 15(2):185-94. PubMed ID: 10803324
[TBL] [Abstract][Full Text] [Related]
18. Intramuscular immunization with plasmid coexpressing tumour antigen and Flt-3L results in potent tumour regression.
Fong CL; Mok CL; Hui KM
Gene Ther; 2006 Feb; 13(3):245-56. PubMed ID: 16163376
[TBL] [Abstract][Full Text] [Related]
19. Prospects for immunotherapy of malignant disease.
Morris EC; Bendle GM; Stauss HJ
Clin Exp Immunol; 2003 Jan; 131(1):1-7. PubMed ID: 12519379
[TBL] [Abstract][Full Text] [Related]
20. 4-1BB is superior to CD28 costimulation for generating CD8+ cytotoxic lymphocytes for adoptive immunotherapy.
Zhang H; Snyder KM; Suhoski MM; Maus MV; Kapoor V; June CH; Mackall CL
J Immunol; 2007 Oct; 179(7):4910-8. PubMed ID: 17878391
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
